【报告导读】在AI投资宏观风险较低、降息周期下全球制造业景气度向上的背景下，会有更多行业的景气度出现改善，投资者可能还是会更加关注增长 率而非股息率。因此在红利策略内部，行业选择上可以更多地向基本面要弹性。跨市场比较来看，港股红利依旧具备性价比，但对于个人投资者而言考虑 到红利税之后可能就没那么明显。 Summary 摘要 1一问红利：2026年是否会有超额？ 2025年红利策略大幅跑输市场，最核心的原因在于市场找到了新的能够突破宏观趋势的成长性：以AI产业投资为代表，以及景气度也开始逐步扩散到与 AI强相关的"泛AI"领域。所以市场的定价驱动力从2022年至2024年上半年的股息率d逐步开始重新转向增长率g。展望2026年，红利策略是否会有相较于全 A的超额收益，核心判断还是在于市场是否依旧以基本面的边际变化作为核心驱动力？基于我们年度策略《世界的中国》对于2026年的基本面展望，在AI 投资宏观风险较低、降息周期下全球制造业景气度向上的背景下，2026年中国的企业盈利修复可能是股票市场的核心驱动力，会有更多的行业景气度出现 改善。在这种宏观背景下，我们认为投资者可能还是会更加关注基本面的边际变化（增长率） ...

Core Viewpoint - The market consensus is gradually shifting towards the initiation of a bull market, but there are significant short-term divergences among investors regarding market conditions and expectations [3][4]. Short-term Market Challenges - The market faces several short-term challenges, including expectations of economic slowdown in Q3 2025 and a policy focus on structural adjustments, which may not support a breakout in indices [2][3]. - The main structural narrative of the bull market has yet to be established, with current high momentum sectors like pharmaceuticals and overseas computing being seen as independent trends rather than the core narrative of the bull market [3][4]. Potential Bull Market Directions - Two potential directions for the bull market structure include: 1. Breakthroughs in domestic technology, particularly in AI and robotics, which could lead to a broader market expansion across infrastructure, hardware, software applications, and business models [3][4]. 2. High global market share manufacturing engaging in anti-involution strategies, which could enhance industry concentration and pricing power [3][4]. Market Sentiment and Future Outlook - The bull market atmosphere is expected to persist despite unfavorable macroeconomic conditions in Q3, as the long-term supply-demand dynamics are projected to improve by 2026 [4][5]. - Key factors that could impact the bull market sentiment include significant demand declines around mid-2026 and constraints on China's manufacturing competitiveness [5][6]. Sector Performance and Investment Opportunities - Short-term strong sectors include pharmaceuticals and overseas computing, which reflect high growth expectations but may face challenges in maintaining independent performance [7][8]. - The defense and military sector is anticipated to have repeated opportunities before early September, while new consumption sectors may see rotational gains [8][10]. - The Hong Kong stock market is highlighted as a potentially leading market in the bull cycle, with a focus on pricing trends that align with fundamental expectations [8][10].

Core Viewpoint - The market consensus is gradually shifting towards the initiation of a bull market, although there remains significant divergence among investors regarding the short-term outlook [1] Summary by Relevant Categories Short-term Market Challenges - The short-term market faces resistance due to expectations of an economic downturn in the third quarter and a policy focus on structural adjustments, which temporarily does not support a breakthrough in index levels [1] - The main narrative of the bull market has yet to be established, indicating that momentum should arise from the core narrative of the bull market [1] Potential Bull Market Drivers - Independent high growth sectors such as pharmaceuticals and overseas computing power are noted, but the main line of the bull market requires broader depth and connotation [1] - Potential directions for the bull market include breakthroughs in domestic technology and high global market share manufacturing industries, which counteract internal competition [1]

Group 1 - Investors generally expect a bull market, but there is increasing divergence regarding the short-term market outlook. Key short-term obstacles include economic downturn expectations for Q3 2025 and a policy focus on structural adjustments, which temporarily do not support an upward breakthrough of the index. The main bull market structure has yet to be established, with potential directions being domestic technological breakthroughs and high global market share manufacturing reversing inward competition [1][5][6] Group 2 - The bull market atmosphere is unlikely to disappear easily. Although the macroeconomic combination in Q3 is unfavorable, it will not affect the expected improvement in the supply-demand structure in 2026, only leading to minor adjustments. Key factors that could genuinely impact the bull market atmosphere include significant demand decline around mid-2026 and the competitiveness of Chinese manufacturing. If the competitive advantage of Chinese manufacturing is constrained, it could undermine the bull market atmosphere [7][8][9] Group 3 - Even if the market experiences adjustments, there will still be opportunities. Before the bull market main line is established, the market can maintain characteristics seen in recent times, such as sector rotation and high micro-activity, with small-cap growth continuing to outperform. This environment is characterized by a lack of demand highlights, a need for time in supply adjustments, and controllable risks in the stock market [9][10] Group 4 - The core view of the market remains unchanged: A-shares may experience fluctuations before early September, with inherent adjustment pressures afterward. Policies to stabilize capital market expectations may be re-initiated. Time is a friend of the bull market, as it supports fundamental improvements and incremental capital inflows. The expectation is that Q4 2025 will perform better than Q3 2025, with 2026 showing further improvements [10][11] Group 5 - Short-term strong sectors such as pharmaceuticals and overseas computing are high-prosperity directions that reflect market expectations for the bull market. However, the relative cost-effectiveness of these sectors has decreased, indicating that future performance may align more closely with the overall market. New consumption is currently a relatively high-cost-effective direction that may see a rotation in the near term [10][11]

1. Report Industry Investment Rating No relevant content provided. 2. Core Views of the Report - The sentiment in the stock market is warm, and the sentiment in the bond market has stabilized. For stock index futures, policies are starting to focus on manufacturing profits. For stock index options, a covered defense strategy is recommended. For treasury bond futures, the bond market sentiment has shown signs of stabilization [1][2]. 3. Summary by Relevant Catalogs 3.1 Market Views Stock Index Futures - **View**: Policies are starting to focus on manufacturing profits. New hot themes are emerging, with the Hengke Innovation Pharmaceutical Index excluding CXO companies and photovoltaic glass promoting production cuts, accelerating capacity clearance and driving up the pharmaceutical and non - ferrous industries. The Central Financial and Economic Commission meeting emphasizes anti - "involution" in some manufacturing industries, which may boost the inflation chain. In the context of mid - year report announcements, attention to pre - announced performance increases may be strengthened. In a warm - sentiment environment, long positions should be maintained, and IM long positions are recommended [1][5]. - **Operation Suggestion**: Allocate IM long positions [5]. - **Market Outlook**: Oscillating with an upward bias [5]. Stock Index Options - **View**: A covered defense strategy is recommended. The trading volume in the options market has been continuously declining, and the trading liquidity is lower than expected. In a low - liquidity derivatives market, sentiment indicators show synchronicity rather than guidance, and the average implied volatility of each option variety has decreased by 0.52%. Given the low liquidity and volatility and the ineffective guidance of sentiment indicators, and the resistance level above the index, a covered defense strategy is advisable [1][5]. - **Operation Suggestion**: Covered defense [5]. - **Market Outlook**: Oscillating [5]. Treasury Bond Futures - **View**: The bond market sentiment has stabilized. After recent adjustments, the bond market sentiment stabilized yesterday. The central bank continued net capital injection, with a net injection of 305.8 billion yuan through reverse repurchase operations. The overall funding situation has eased, and the DR007 rate has slightly declined. The policy announced by the National Development and Reform Commission was in line with expectations, and the stock - bond seesaw effect has weakened. The market may be pre - gambling on June PMI data and the central bank's bond - buying restart. However, caution should still be exercised, and attention should be paid to June PMI data and central bank operations [2][5][6]. - **Operation Suggestion**: Trend strategy: Oscillating. Hedging strategy: Pay attention to short - position hedging at low basis levels. Basis strategy: Appropriately pay attention to basis widening. Curve strategy: Steepening the yield curve in the medium - term has higher odds [6]. - **Market Outlook**: Oscillating [5][6]. 3.2 Economic Calendar - China's official manufacturing PMI for June was 49.7, up from the previous value of 49.5. The final value of the US Markit manufacturing PMI for June was 52.9, higher than the previous and predicted values of 52. The US unemployment rate and non - farm payrolls for June are yet to be announced [7]. 3.3 Important Information and News Tracking - **Domestic Macroeconomics**: From January to May, the added value of large - scale electronic information manufacturing enterprises increased by 11.1% year - on - year, 4.8 and 1.6 percentage points higher than the overall industry and high - tech manufacturing respectively. In May, the added value increased by 10.2% year - on - year. Mobile phone production was 570 million units, a year - on - year decrease of 6.5%, with smartphone production at 450 million units, a 2.1% decrease. Microcomputer equipment production was 130 million units, a 5.5% increase, and integrated circuit production was 193.5 billion pieces, a 6.8% increase [7]. - **Pharmaceutical Industry**: The National Healthcare Security Administration and the National Health Commission issued measures to support the high - quality development of innovative drugs, including supporting the use of healthcare insurance data for innovative drug R & D, strengthening information sharing among medical, healthcare insurance, and pharmaceutical sectors, and providing necessary healthcare insurance data services for innovative drug R & D on the premise of data security and compliance [8].